ArticleJournal of clinical hypertension (Greenwich, Conn.)2025
Accuracy and Reduced Sleep Disruption of a Wearable Smartwatch for Nocturnal Blood Pressure Monitoring: A Validation Study.
Article in Journal of clinical hypertension (Greenwich, Conn.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Confounding Role of Cuff-Induced Sleep Fragmentation on Nighttime Blood Pressure Variability Reproducibility.Journal of clinical hypertension (Greenwich, Conn.) · 2026Article
- Accuracy and Reduced Sleep Disruption of a Wearable Smartwatch for Nocturnal Blood Pressure Monitoring: A Validation Study.Journal of clinical hypertension (Greenwich, Conn.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Nocturnal blood pressure is a significant predictor of cardiovascular risk, but traditional ambulatory blood pressure monitoring (ABPM) can disrupt sleep. This study aimed to validate the accuracy of the Huawei Watch D2 (WD2), a wrist-worn oscillometric device, and assess its impact on sleep quality compared to conventional ABPM. This prospective, single-center trial first validated the WD2 against a mercury sphygmomanometer in 85 participants according to ANSI/AAMI/ISO 81060-2:2018 standards in both seated and supine positions. Subsequently, the device's nocturnal accuracy and sleep impact were compared against a traditional ABPM device in 46 participants over a three-night protocol. The WD2 met all ISO accuracy standards. During nighttime monitoring, there was no significant difference between the WD2 and ABPM for mean systolic or diastolic blood pressure. However, the number of awakenings was significantly lower on nights with the WD2 alone compared to nights with the ABPM device (p = 0.016). In conclusion, the Huawei Watch D2 is a clinically validated device that provides nocturnal blood pressure readings comparable to traditional ABPM with the significant advantage of minimal sleep disruption, positioning it as a valuable alternative for nocturnal hypertension monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.